Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
03/30 IMPAX LABORATORIES : Announces Favorable Ruling Regarding Patent Validity for Zo..
03/28 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Entry into a Material Defi..
03/28 IMPAX LABORATORIES INC : Entry into a Material Definitive Agreement (form 8-K)
03/27 IMPAX LABORATORIES : DuPont, Impax Labs gain, G-III Apparel slides
03/27 IMPAX LABORATORIES INC : Change in Directors or Principal Officers, Amendments t..
03/27 IMPAX LABORATORIES : Board of Directors Appoints Paul M. Bisaro President and CE..
03/01 IMPAX LABORATORIES : Management's Discussion and Analysis of Financial Condition..
03/01 IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Results of Operations and ..
03/01 IMPAX LABORATORIES INC : Results of Operations and Financial Condition, Regulati..
03/01 IMPAX LABORATORIES : Labs reports 4Q loss
More news
Sector news : Pharmaceuticals - NEC
03/30 China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/30DJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/27 Midday Gainers / Losers
03/27 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
03/27 New chief at Impax Labs; shares up 12% premarket
03/27 PREMARKET GAINERS AS OF 9 : 05 am
03/16 Impax Laboratories (IPXL) Presents At Barclays Global Healthcare Conference 2..
Advertisement
Financials ($)
Sales 2017 819 M
EBIT 2017 110 M
Net income 2017 16,0 M
Debt 2017 443 M
Yield 2017 -
P/E ratio 2017 64,80
P/E ratio 2018 24,05
EV / Sales 2017 1,70x
EV / Sales 2018 1,60x
Capitalization 948 M
More Financials
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 12,3 $
Spread / Average Target -4,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
J. Kevin Buchi President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC-3.02%948
JOHNSON & JOHNSON9.07%338 645
ROCHE HOLDING LTD.8.81%221 440
PFIZER INC.5.70%204 439
NOVARTIS AG-0.47%197 239
MERCK & CO., INC.8.10%174 728
More Results